Equity crowdfunding is a relatively new way for companies to raise capital. It gives people the opportunity to invest without having millions of dollars. The concept hasn't quite taken off in popularity, but some companies are already using it to their advantage. Aristotle Loumis, Founder and CEO of Ellison Eyewear, shares how his company used the new tool to get off the ground. Since launching, sunglass maker Ellison Eyewear has raised about $300,000 using various types of crowdfunding, some of which was through cryptocurrency. Loumis says he was inspired to create the company after a trip to Greece. All of the company's products are created in family-owned workshops in Greece. Ellison Eyewear features a "loss-insured" membership. For people who are prone to losing their sunglasses, customers can get replacements without paying full price for a new pair.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More